The 7 most recent market catalysts affecting $IDXX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 65
IDEXX Laboratories Announces Acquisition Of Veterinary AI Clinical Workflow Software Firm CoVetAI; Terms Not Disclosed
This acquisition by IDEXX Laboratories (IDXX) is a moderate corporate catalyst, signaling their commitment to integrating AI into veterinary clinical workflows. While the financial…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710
Barclays analyst Glen Santangelo maintained an 'Overweight' rating on IDEXX Laboratories, signaling a continued belief in the company's long-term prospects. However, the price targ…
Aug 11, 2026
Corporate Catalyst
Neutral
Impact 65
IDEXX Announces Launch Of Catalyst proBNP Test For Assessing Heart Disease In Cats And Dogs, Available In North America Beginning October 2026
IDEXX's launch of the Catalyst proBNP test is a strategic move to capture a larger share of the growing veterinary cardiology diagnostics market. This new offering enhances their p…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 92
Why Is IDEXX Laboratories Stock Gaining Tuesday?
IDEXX Laboratories' Q2 earnings and revenue significantly exceeded analyst expectations, primarily fueled by strong growth in its Companion Animal Diagnostics segment. This positiv…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
IDEXX Laboratories shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 GAAP EPS guidance above estimates.
This headline is a significant corporate catalyst for IDEXX Laboratories, directly impacting its stock positively due to better-than-expected earnings and an optimistic future outl…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate
IDEXX Laboratories announced impressive Q2 results, with EPS of $4.27 significantly beating the $3.96 estimate and sales of $1.217 billion surpassing the $1.201 billion estimate. T…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $620
UBS analyst Andrea Alfonso maintained a 'Neutral' rating on IDEXX Laboratories but lowered the price target from $640 to $620. This action indicates a slightly reduced valuation ex…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.